Skip to main content
. 2016 May 5;14(1):234–242. doi: 10.3892/mmr.2016.5212

Figure 3.

Figure 3

Transplanted Akt-AFMSCs improve cardiac function at day 21 post-ischemia-reperfusion injury. Shown are the (A) fractional shortening (%) and (B) ejection fractions (%) for all treatment groups. *P<0.05 vs. control, #P<0.05 vs. AFMSCs. Data were obtained from n=8 animals/group. AFMSCs, amniotic fluid-derived mesenchymal stem cells.